Autopsy report · NCT03321747
Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
Cause of deathFunding or business
“After completion of Phase I, it was decided not to initiate Phase II of the study.”
Life of this trial
- Ran for about 2 years 9 months before it stopped.
- 13 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Conditions
- Lung Cancer
- Interventions
- Stereotactic Ablative Body Radiation (SABR)
- Participants
- 13
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
“Due to lack of funding, phase II of study was not completed.” - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
“This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” - Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
“Study closed following Phase I portion, insufficient activity to continue to Phase II.” - Assessment of Thoughts and Feelings Occurring During and After a Meal
“Decision was made not to start the study before it was initiated.” - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
“Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.